| 0.94 0.052 (5.87%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.23 |
1-year : | 1.44 |
| Resists | First : | 1.05 |
Second : | 1.23 |
| Pivot price | 0.9 |
|||
| Supports | First : | 0.82 |
Second : | 0.68 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 0.88 |
| MA(100) : | 1.21  |
MA(250) : | 1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 56 |
D(3) : | 51.3 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 3.86 | Low : | 0.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RANI ] has closed below upper band by 35.1%. Bollinger Bands are 32.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.96 | 0.96 - 0.96 |
| Low: | 0.86 - 0.87 | 0.87 - 0.87 |
| Close: | 0.93 - 0.94 | 0.94 - 0.95 |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Fri, 01 May 2026
MSN Money - MSN
Fri, 01 May 2026
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Thu, 30 Apr 2026
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Sun, 26 Apr 2026
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Thu, 16 Apr 2026
Rani Therapeutics (NASDAQ: RANI) sets 2026 virtual meeting on board elections and auditor - Stock Titan
Thu, 09 Apr 2026
Drug approval veteran joins Rani to shape oral biologics push - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 100 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 49.5 (%) |
| Shares Short | 10,110 (K) |
| Shares Short P.Month | 11,540 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | -584.2 % |
| Return on Assets (ttm) | -50.3 % |
| Return on Equity (ttm) | -182 % |
| Qtrly Rev. Growth | 42 % |
| Gross Profit (p.s.) | 0.01 |
| Sales Per Share | 0.01 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -2.09 |
| PEG Ratio | 0 |
| Price to Book value | 2.76 |
| Price to Sales | 57.55 |
| Price to Cash Flow | -5.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|